Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

Specimen Handling 150pembrolizumab 132Magnetic Resonance Spectroscopy 120Cyclophosphamide 118Biopsy 106fludarabine 90Nivolumab 61Carboplatin 55Radiotherapy 49Cisplatin 49Gemcitabine 48venetoclax 43Paclitaxel 43Cetuximab 40fludarabine phosphate 39Ipilimumab 36Fluorouracil 35atezolizumab 34Bevacizumab 33durvalumab 30Radiation 30Oxaliplatin 29X-Rays 28Leucovorin 28Dexamethasone 28Azacitidine 27Irinotecan 26Cytarabine 26Radiosurgery 24Injections 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Histamine Antagonists × 90 days × Clear all
NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡